Recombinant Human VSIG8 Fc Chimera Protein, CF Summary
Product Specifications
| Human VSIG8 (Val22-Gly263) Accession # Q5VU13 | IEGRMD | Human IgG1 (Pro100-Lys330) |
| N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
9200-VS
| Formulation | Lyophilized from a 0.2 μm filtered solution in Sodium Acetate, Mannitol and Trehalose. |
| Reconstitution | Reconstitute at 200 μg/mL in Water. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
Recombinant Human VSIG8 Fc Chimera (Catalog # 9200-VS) inhibits anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 1-5 μg/mL.
Reconstitution Calculator
Background: VSIG8
VSIG8 (V-set and immunoglobulin domain containing 8), also known as C1orf204, is an approximately 45 kDa type I transmembrane protein of the B7 family within the Ig superfamily. Mature human VSIG8 consists of a 242 amino acid (aa) extracellular domain (ECD) containing two V-type Ig-like domains, a 21 aa transmembrane domain, and a 130 aa cytoplasmic domain. Within the ECD, human VSIG8 shares 88% and 89% aa identity with mouse and rat VSIG8, respectively. Alternative splicing generates a long isoform of human VSIG8 with a substitution in the cytoplasmic juxtamembrane region and a 124 aa extension at the C-terminus. VSIG8 was identified from proteomic analysis of human hair shafts (1, 2). It is expressed in the hair follicle and shaft, superficial layers of the nail matrix, and superficial layers of oral epithelium (3). R&D Systems in-house testing indicates that VSIG8 inhibits the production of IL-2 by activated T cells.
- Rice, R.H. et al. (2010) J. Proteome Res. 9:6752.
- Lee, Y.J. et al. (2006) Mol. Cell. Proteomics 5:789.
- Rice, R.H. et al. (2011) J. Invest. Dermatol. 131:1936.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human VSIG8 Fc Chimera Protein, CF
Average Rating: 5 (Based on 1 Review)
Have you used Recombinant Human VSIG8 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
